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Abstract
The Polycomb group protein EZH2 is a transcriptional
repressor involved in controlling cellular memory and
has been linked to aggressive and metastatic breast
cancer. Here we report that EZH2 decreased the ex-
pression of five RAD51 paralog proteins involved in
homologous recombination (HR) repair of DNA double-
strand breaks (RAD51B/RAD51L1, RAD51C/RAD51L2,
RAD51D/RAD51L3, XRCC2, and XRCC3), but did not
affect the levels of DMC1, a gene that only functions
in meiosis. EZH2 overexpression impaired the forma-
tion of RAD51 repair foci at sites of DNA breaks. Over-
expression of EZH2 resulted in decreased cell survival
and clonogenic capacity following DNA damage in-
duced independently by etoposide and ionizing radia-
tion. We suggest that EZH2 may contribute to breast
tumorigenesis by specific downregulation of RAD51-
like proteins and by impairment of HR repair. We pro-
vide mechanistic insights into the function of EZH2
in mammalian cells and uncover a link between EZH2,
a regulator of homeotic gene expression, and HR DNA
repair. Our study paves the way for exploring the block-
ade of EZH2 overexpression as a novel approach for
the prevention and treatment of breast cancer.
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Introduction
Breast cancer is the most common malignancy and second
leading cause of cancer-related deaths in women in the
Western world [1]. Despite advances in early detection and
treatment, once distant metastases develop, the disease is
(at present) incurable. There is a need to better understand
themolecular events that lead to breast cancer development
and progression to improve the design of clinical tests and
novel targeted treatments.
Perturbations of the transcriptional memory of a cell
may lead to developmental defects and cancer [2,3]. Two
groups of proteins have long been found to be involved
in the maintenance of heritable transcription patterns: the
Polycomb group proteins (PcG) and their counterpart, the
Trithorax group proteins (TrxG) [3]. Both maintain spatial
patterns of homeotic box gene expression, which occur early
during embryonic development of Drosophila. TrxG act as
activators and maintain the ‘‘on stage’’ of gene expression,
whereas PcG act as repressors and maintain the ‘‘off stage’’
of gene expression. At least two PcG complexes with distinct
functions and target genes have been found: Polycomb Re-
pression Complex (PRC)-2, which consists of EZH2/embryonic
ectoderm development (EED) [4] and Su(z)12 [5], among other
proteins, and PRC-1 [6], which consists of Ring1, Mel18, Mph1,
Bmi1, and Mpc2, among other proteins. In human malignan-
cies, PcG and TrxG have been found to be dysregulated first
in neoplasms of hematopoietic origin, but also in solid tumors,
including breast and prostate carcinomas [7–16].
EZH2 is the human homologue of the PcG Enhancer of
Zeste and is involved in gene silencing [3]. EZH2 contains
a SET domain, a highly conserved domain found in many
chromatin-associated histone methyltransferases. EZH2 and
its binding partners EED and Suz(12) interact directly with
type 1 histone deacetylases (HDACs), and this has been sug-
gested to be part of the silencing mechanism [17–19]. Fur-
thermore, recent studies have demonstrated that PRC-2
complexes methylate H3-K9 and K27 in vitro, with a strong
preference for K27 [20–25]. Methylation of both H3-K9 and H3-
K27 is thought to be involved in targeting PRC-1 to specific
genetic loci [23,26]. At present, the mechanism of function of
EZH2 in the development of malignant tumors is unknown.
The mammalian genome is at constant risk of mutation as
a result of damage to DNA. This can occur due to extrinsic or
intrinsic insults. Hampered DNA double-strand break (DSB)
repair may lead to structural chromosomal abnormalities and
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aneuploidy, which may result in cell death or neoplastic trans-
formation [27–30]. The two main mechanisms used to repair
DSB are homologous recombination (HR), which promotes
accurate repair of DSB by copying intact information from an
undamaged homologous DNA template, and nonhomologous
end joining (NHEJ), which is a homology-independent mecha-
nism that rejoins broken ends, regardless of sequence [31].
In vertebrates, HR requires the recombinase RAD51 and
its five paralogs RAD51B/RAD51L1, RAD51C/RAD51L2,
RAD51D/RAD51L3, XRCC2, and XRCC3 [32]. The sixth
paralog, DMC1, is thought to be only active in meiotic cells
[32,33]. The RAD51 paralogs share up to 20% amino acid
identity with the human RAD51 protein and with each other.
Null mutations of any of the paralogs prevent RAD51 from
assembling at damaged sites, resulting in decreased RAD51
repair foci formation, hampered HR, and increased sensi-
tivity to DNA cross-linking drugs [34–40]. Although the
functions and mechanisms of the regulation of the RAD51
paralogs are still elusive, an emerging body of data indicates
that the RAD51 paralogs are important in maintaining chro-
mosomal integrity and function in the early and later stages
of HR [32,41].
We have previously reported that overexpression of the
PcG EZH2 plays an important role in breast cancer by pro-
moting the growth and invasion of breast epithelial cells [14].
Moreover, EZH2 is a promising novel biomarker of aggres-
sive breast cancer, being elevated in invasive and metastatic
tumors, when compared to normal breast tissues. Indeed,
EZH2 is an independent predictor of breast cancer recur-
rence and death [14]. In breast tissues, EZH2 protein ex-
pression increases steadily from normal epithelium to
epithelial hyperplasia, ductal carcinoma in situ, invasive car-
cinoma, and distant metastasis, supporting the finding that
EZH2 plays a central role in neoplastic transformation [14].
In this study, we show that EZH2 overexpression down-
regulates all five RAD51 paralogs, which are necessary for
HR in breast epithelial cells. This downregulation is associ-
ated with an impaired survival capacity of breast epithelial
cells amidst the DNA-damaging effects of etoposide and
ionizing radiation. Taken together, these data uncover a link
between regulators of homeotic gene expression and the
DNA repair pathway, and they propose a novel mechanism
for EZH2 function in breast tumorigenesis.
Experimental Design
Cell Lines
Spontaneously immortalized human mammary epithelial
MCF10A cells (ATCC, Manassas, VA) were grown in DMEM/
F-12 (Cellgro) supplemented with nonessential amino acids,
penicillin/streptomycin, L-glutamine, Fungizone, 5% horse
serum, 20 ng/ml embryonic growth factor, 100 ng/ml cholera
toxin, 10 mg/ml insulin, and 500 ng/ml hydrocortisone. Cells
were kept at 37jC and 10% CO2. For detaching, cells were
treated with 0.25% trypsin for 5minutes. MCF7 breast cancer
cells (ATCC) were grown in a DMEM/F12 mixture supple-
mented with 5% FBS. SUM102 human breast cancer cells
were grown in F12 supplemented with 5% FBS, 10 mg/ml
insulin, and 500 ng/ml hydrocortisone.
Adenoviral Constructs
Adenoviral constructs were generated by in vitro recom-
bination. Full-length EZH2 (av-EZH2) was inserted into an
adenoviral shuttle [pACCMVpLpA() loxP-SSP] provided
by the University of Michigan (Ann Arbor, MI) vector core.
The virus was complemented in a 293 helper cell line, propa-
gated in 911 cells, and purified on a CsCl gradient. The virus
was stored in 10 mM Tris–HCl (pH 7.4), 137 mM NaCl, 5 mM
KCl, and 1 mM MgCl2 in 10% (vol/vol) glycerol. As control,
adenovirus containing no transgene was used. As an addi-
tional control, the full-length luciferase gene, an unrelated
gene, was inserted in an adenovirus (av-luciferase).
Quantitative Reverse Transcriptase Analysis
RNAwasharvested fromMCF10Acells infectedwith vector
or av-EZH2 constructs using TRIZOL (Invitrogen, Carlsbad,
CA), according to the manufacturer’s instructions. One micro-
gram of RNA was reverse-transcribed using Superscript II
(Invitrogen) following the manufacturer’s instructions and re-
constituted in 20 ml of RNAse-free water. One microliter of
cDNA product was used for quantitative real-time PCR analy-
sis. Reaction mixes were made by combining 12.5 ml of 2
SYBR green RT-PCR master mix, 0.5 ml of RNAse inhibitor
(Promega, Madison, WI), primer, template, and H2O to a final
volume of 25 ml into Smart Cycler Tubes (Cepheid, Sunnyvale,
CA). Primers were used at a final concentration of 0.25 mM:
RAD51L1: 5V-TTT CCC CAC TGG AGC TTA TG-3V, 5V-
CTT CGT CCA AAG CAG AAA GG-3V
RAD51L2: 5V-GCA TAC CCA GGG CTT CAT AAT C-3V,
5V-TTT CGG TGT TCC TCT CCC TTG TGT TTT TCT-3V
RAD51L3: 5V-CAG TGG TGG ACC TGG TTT CT-3V, 5V-
CTG GGC CTC CTA CAA TTT CA-3V
XRCC2: 5V-TTC CAT AGG GCT GAG TCT GG-3V, 5V-
CCG GAG CAT ATC AAA GTG GT-3V
XRCC3: 5V-AAG AAG GTC CCC GTA CTG CT-3V, 5V-
AAA CAC GTT CGT CCC AGA AC-3V
DMCI: 5V-AAT GGC ACT TTT TCG AGT GG-3V, 5V-CAG
GCA TCT CAG GAC TGT CA-3V
b-Actin: 5V-CTG GAC TTC GAG CAA GAG-3V, 5V-AAG
GAA GGC TGG AAG AGT-3V.
Primers were selected using LocusLink software and
spanned an intron–exon junction to prevent amplification of
genomic DNA. To confirm the absence of nonspecific ampli-
fication, a no-template control was included. Forty cycles were
programmed as follows: 15 seconds of denaturation at 94jC,
followed by 1minute of extension at 60jC. Results were quan-
tified against a b-actin standard set in relation to the vector
control using Excel.
Western Immunoblot
MCF10A, MCF7, and SUM102 cells were infected with
vector or av-EZH2. After 2 days, cells were lysed in 10%
glycerol, 150 mM KCl, 10 mM MgCl2 25 mM HEPES, 2 mM
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DTT, and one Complete Mini protease inhibitor tablet (Roche,
Nutley, NJ) and sonicated 4  30 seconds at medium speed.
Samples were separated on a precast gel (10% Tris–glycine;
Cambrex, Rockville, MD) and transferred to nitrocellulose
membrane using a Transblot Semidry Transfer Cell (Bio-
Rad, Hercules, CA). Membranes were blocked in 5% (wt/vol)
milk at room temperature for 1 hour. After threewashes in Tris-
buffered saline–Tween (TBS-T), primary antibodies against
RAD51L2 (Abcam, Cambridge, MA), RAD51L3 (Novus Bio-
logicals, Littleton, CO), RAD51L3, XRCC2, and XRCC3 (Ab-
cam), at a dilution of 1/1000, were added in PBS-T [PBS
containing 0.1% (vol/vol) Triton X-100] containing 3% BSA.
The membranes were incubated overnight at 4jC, washed
three times for 15 minutes in TBS-T, and incubated with anti–
mouse horseradish peroxidase (Amersham, Buckingham-
shire, UK) at a dilution of 1/2500. After incubation for 1 hour
and three more washes, immunoreactive proteins were visu-
alized using ECL reagents (Amersham), following the manu-
facturer’s instructions.
Immunofluorescence
MCF10A cells were plated onto chamber slides and
infected with av-EZH2 or av-vector. On the next day, the cells
were treated with 0.3 mM etoposide for 24 hours. Following
incubation, the cells were washed three times with PBS and
fixed in 3% (wt/vol) paraformaldehyde in PBS-T and 0.15%
(wt/vol) BSA for 20 minutes. Prior to incubation with anti-
bodies against RAD51 (Santa Cruz Biotechnology, Santa
Cruz, CA) or Myc (Cell Signaling, Beverly, MA) at a dilution
of 1/1000 for 16 hours, the slides were rinsed twice in PBS-T.
After incubation, the slides were washed 4  15 minutes in
PBS-T. The slides were incubated for 4 hours with Alexa Fluor
488 or Texas Red antibody (Molecular Probes, Carlsbad, CA)
at a dilution of 1/500, washed 4  15 minutes in PBS-T, and
mounted with ProLong antifade reagent with DAPI (Molecular
Probes). Images were obtained with an Olympus F500
inverted confocal microscope using 10, 40, and 60 oil
immersion objectives. The frequencies of cells containing
RAD51 foci were determined by counting at least 250 nuclei
in each slide in three independent experiments. Following
strict published criteria, only nuclei containingz10RAD51 foci
were classified as RAD51-positive [42].
Survival Assays
For colony outgrowth assays, 500 MCF10A, 500 MCF7,
and 500 SUM102 cells were plated onto a Petri dish 4 hours
before infection. Cells were infected with vector or av-EZH2
constructs. An av-luciferase was used as additional control.
One day after infection, the culture medium was changed
and cells were continuously treated with increasing concen-
trations of etoposide (0.1, 0.3, and 0.5 mM). After 7 to 9 days,
when colonies had been observed, the cells were washed
twice in PBS, and colonies were fixed and stained using
methylene blue (Merck, Whitehouse Station, NJ), following
the manufacturers’ instructions. Colonies with more than
50 cells were counted as positive.
For clonogenic survival assays, 500 MCF10A, 500 MCF7,
and 500 SUM102 cells were plated 4 hours before infection.
Cells were infected with av-vector, av-EZH2, or av-luciferase
constructs. One day after infection, the culture medium was
changed and cells were treated for 24 hours with increasing
concentrations of etoposide (0.1, 0.3, and 0.5 mM). After 7
to 9 days, colonies were already visible. Cells were washed
twice with PBS, fixed, and stained using methylene blue
(Merck), following the manufacturer’s instructions. Colonies
exceeding 50 cells were counted.
For ionizing radiation experiments, 4000 MCF10A, 4000
MCF7, and 4000 SUM102 cells were plated and infected with
av-vector, av-EZH2, or av-luciferase. Two days after infection,
the cells were irradiated with doses of 0, 300, 600, 900, and
1200 rad using a 137Cs Mark I irradiator. Seven days post-
infection, the colonies were stained with crystal violet and
counted as described in the above paragraph. For all assays,
transient gene expression of EZH2 in MCF10A, MCF7, and
SUM102 cells was validated by Western blot analysis.
Metaphase Analysis
MCF10A cells were grown to 20% confluency and
infected with av-EZH2 or vector control. Two days postin-
fection, 0.004 mg/ml KaryoMax Colcemid (Gibco, Carlsbad,
CA) was added. Sixteen hours later, the cells were trypsi-
nized and washed in PBS. After centrifugation, the cells were
resuspended in 250 ml of PBS. Eight milliliters of 0.06 M KCl
was carefully added while gently shaking the cells at 37jC in
a water bath. Cells were incubated at 37jC for 30 minutes
and then fixed with 2 ml of methanol:glacial acetic acid (3:1).
After 5 minutes of centrifugation at 1000 rpm, the cells were
resuspended in 8 ml of fixative, centrifuged again, and finally
resuspended in 1 ml of fixative.
Cells were dropped from a pipette onto a wet frosted
slide (Fisher, Pittsburgh, PA) from a height of about 50 cm.
The slides were dried for 15 minutes at 37jC. ProLong Gold
(Molecular Probes) antifade reagent with DAPI was used to
fix the cover slip. Slides were dried overnight and then ana-
lyzed using Spectral Imaging SkyView software (Applied
Spectral Imaging, Vista, CA). The number of chromosomes
in 75 to 100 cells in metaphase was counted independently
by three investigators (M.Z., D.O.F., and C.G.K.). Experi-
ments were performed in triplicate.
Results
EZH2-Overexpressing Mammary Epithelial Cells Exhibit
Lower Transcription of RAD51L1, RAD51L2, RAD51L3,
XRCC2, and XRCC3, But Not of DMC1
In our previous studies, we demonstrated that EZH2
promoted growth and invasion in human mammary epithelial
cells, which resulted in an aggressive and metastatic breast
cancer phenotype [14]. Patients with tumors with high EZH2
expression had a worse disease-free and overall survival
than those with low levels of EZH2 [14]. EZH2 has been
reported to function as a transcriptional repressor in mam-
malian cells [14,19,43]. Preliminary data from our laboratory
of a cDNA microarray comparing EZH2-overexpressing
breast epithelial cells to vector controls prompted us to
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investigate the possible influence of EZH2 on the expression
of the RAD51 paralogs (data not shown). Notably, quantita-
tive real-time PCR on av-EZH2– and av-vector– infected
human mammary epithelial cells revealed that EZH2 over-
expression led to a drastic decrease in the transcripts of
the five RAD51 paralogs. As shown in Figure 1A, RAD51L1,
RAD51L2, RAD51L3, XRCC2, and XRCC3 transcripts are
significantly decreased in EZH2-overexpressing MCF10A
cells. These five RAD51 paralogs have crucial nonredun-
dant roles in the HR DNA repair pathway. DMC1, a RAD51
paralog that is active only in meiosis, was not affected
(Figure 1A). Immunoblot analyses of MCF10A, MCF7, and
SUM102 cells showed that EZH2 overexpression was asso-
ciated with decreased protein levels of RAD51L1, RAD51L2,
RAD51L3, XRCC2, and XRCC3 (Figure 1B).
Attenuated RAD51 Repair Foci Formation in
EZH2-Overexpressing Breast Epithelial Cells
RAD51L1, RAD51L2, RAD51L3, XRCC2, and XRCC3 are
required for the formation of DNA damage–induced RAD51
repair foci. This is a crucial event in HR repair as studies
have demonstrated that RAD51 foci formation is signifi-
cantly attenuated in mutant cells defective in any of the
RAD51 paralogs [34–37,40,41,44,45]. EZH2 overexpres-
sion in MCF10A cells resulted in a marked decrease in
RAD51 foci formation after induction of DSB by etoposide
(Figure 2). To investigate the effect of EZH2 overexpression
on the repair foci formation ability of breast cells, we deter-
mined the number of cells with z10 RAD51 foci in EZH2-
overexpressing and control cells at 0, 6, 12, and 24 hours
following a 24-hour treatment with etoposide. Figure 2B
shows that, immediately after removal of etoposide, EZH2-
overexpressing cells displayed only about 50% of repair foci
compared to the controls. These cells could not compensate
for the hampered foci formation by sustaining a low level
of repair over a longer period of time. Thus, 6 hours after
etoposide withdrawal, the number of cells with RAD51 foci
was significantly decreased in all cells, but the number of
foci in EZH2-overexpressing cells was still significantly
lower than that in the respective controls. After 12 hours,
EZH2-overexpressing cells and controls had about the
same number of cells with RAD51 repair foci. Twenty-four
hours after etoposide withdrawal, RAD51 foci formation
ceased almost completely in EZH2-overexpressing cells
and controls. These data suggest that HR repair in EZH2-
overexpressing cells is less effective than that in the controls.
EZH2-Overexpressing Cells Have Reduced Survival
to Etoposide- and Radiation-Induced DNA Damage
and Increased Number of Chromosomes
The above experiments demonstrated that EZH2 over-
expression results in a marked downregulation of the RAD51
paralogs involved in HR and an attenuated formation of
RAD51 foci after induced DSB. We next investigated the
effects of EZH2 overexpression on cell survival after induc-
tion of DSB in the spontaneously immortalized human mam-
mary epithelial cell line MCF10A and two breast cancer cell
lines MCF7 and SUM102. In addition, to control for possible
effects of protein overexpression, we infected these cells
with av-luciferase, a gene unrelated to EZH2 that is not
involved in HR repair. To induce DSB, we chose to indepen-
dently use etoposide and ionizing radiation—both previously
shown to cause DNA DSBs that are repaired by the HR path-
way [42]. As presented in Figure 3, EZH2 overexpression
significantly decreased the survival, clonogenic capacity, and
colony-forming ability of the three breast cell lines after ex-
posure to ionizing radiation and etoposide. Overall, our ex-
periments suggest that overexpression of EZH2 hampers
HR repair of DSB, at least in part, by downregulation of
the five RAD51 paralogs RAD51L1, RAD51L2, RAD51L3,
XRCC2, and XRCC3.
Knockout of the RAD51 paralogs has been shown to
cause multiple forms of genetic instability, including chromo-
some aberrations, centrosome fragmentation, andmissegre-
gation of chromosomes [32,34–37,40,41,44,45]. In particular,
a defect in chromosomal segregation leading to aneuploidy
appears to be specific for HR repair defects, as it has not
been found for cells deficient in alternative repair pathways (for
Figure 1. RAD51L1, RAD51L2, RAD51L3, XRCC2, and XRCC3 transcripts
and proteins are downregulated in EZH2-overexpressing mammary epithelial
cells. (A) Quantitative real-time PCR. The graph shows transcription of the
RAD51 paralogs in EZH2-overexpressing cells relative to control cells. Stan-
dard deviations from at least three independent experiments are depicted.
The transcription of the five RAD51 paralogs involved in HR is significantly
downregulated. Only DMC1, which is active in meiotic cells, stays unmodi-
fied. (B) Western immunoblots for EZH2 and the five RAD51 paralogs in
EZH2-overexpressing MCF10A, MCF7, SUM102 cells and in vector-infected
controls. A representative -actin is shown for MCF10A cells. -Actin is
shown for MCF7 and SUM102 cells.
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instance, simple end joining of DNA breaks) [32,46,47]. Cyto-
genetic analysis of EZH2-overexpressing MCF10A cells and
vector controls showed that EZH2 overexpression led to a
shift in the number of chromosomes. Table 1 shows that, al-
though the control cells show the characteristic chromo-
somal changes of immortal but untransformed MCF10A cells,
EZH2-overexpressing cells have an increased number of
chromosomes, with over 65% of cells having 49 to 54 chromo-
somes (t-test, P < .0001). Adenovirus infection did not affect
the number and integrity of the chromosomes, as adenovirus-
infected and uninfected MCF10A cells had the same low-level
(baseline) aneuploidy characteristic of MCF10A cells [48–53].
Discussion
In this study, we provide evidence for a hitherto unknown
mechanism of action for EZH2 in the development of breast
cancer. We report that EZH2 overexpression results in
specific downregulation of five RAD51 paralogs RAD51L1,
RAD51L2, RAD51L3, XRCC2, and XRCC3, which are
crucial for the normal function of the HR pathway of DNA
DSB repair in mammalian cells [36,37,40]. Coupled with this
effect on gene expression, EZH2 overexpression attenuates
RAD51 foci formation at sites of DNA damage, impairing the
ability of human breast epithelial cells to repair DNA by HR.
Our results show that EZH2 overexpression leads to a lower
survival after DNA-damaging insults. We suggest that sup-
pression of the RAD51 paralogs by EZH2 is a likely mecha-
nism of EZH2-driven malignant transformation of breast
epithelial cells.
EZH2 is a member of the PcG of early-onset gene re-
pressors involved in maintaining heritable gene expression
profiles, thus regulating cell type identity [22–25]. There is
compelling evidence that EZH2 overexpression leads to
cancer. EZH2 is involved in the pathogenesis of myeloid
leukemia, Hodgkin’s disease, B-cell lymphoma, and multiple
myeloma [9,10,12]. Our group and other investigators have
reported that EZH2 promotes the development and progres-
sion of breast cancer, prostate cancer, and other solid tumors
[11,13–15]. By performing an in silico analysis of published
cDNA datasets using ONCOMINE [54], we found that, in
addition to breast cancer, EZH2 mRNA is overexpressed in
lung, liver, prostate, bladder, and adrenal carcinomas when
compared to their normal epithelial counterparts (data not
shown). These data suggest that misexpression of EZH2
may be a fundamental event in the transition from normal
state to cancer in several organs. At present, the mechanism
of action of EZH2 in cancer is unknown.
There are several lines of evidence supporting a role for
the RAD51 gene family in cancer development, especially in
light of the functional links between RAD51 and the BRCA
genes [32]. In breast cancer, it has been shown that BRCA2
mutation carriers are at greater risk for breast cancer when
they also carry the RAD51 variant G135CD [55–57]. XRCC2
codon 188 variant may carry an increased risk for breast
cancer [58]. The variant Glu233Gly of RAD51L3 may in-
crease the risk of breast cancer in families without BRCA
gene mutations [59]. The emerging association between the
RAD51 gene family and cancer is not surprising given the
critical role of RAD51 and its paralogs in HR repair, which is
essential for the maintenance of genomic stability and tumor
avoidance. Cell lines deficient in XRCC2 and XRCC3 have
a high frequency of chromosomal instability, with especially
high frequencies of chromosome exchange and aneuploidy
[32,46,47,60]. XRCC2- and XRCC3-deficient hamster cells
have been shown to have increased missegregation of
chromosomes resulting in aneuploidy, likely due to a centro-
some defect [46,47]. It has been suggested that loss of
RAD51 paralog genes leads, in particular, to a chromosomal
segregation defect that results in aneuploidy [32,46,47].
Studies have shown that aneuploidy causes imbalances in
groups of proteins involved in chromosome segregation,
synthesis, and repair, possibly leading to malignant trans-
formation of the cell [27–30].
In the present study, we found that EZH2 overexpression
in human mammary epithelial cells resulted in a drastic
downregulation of the transcripts of the five RAD51 paralogs
involved in HR repair (RAD51L1, RAD51L2, RAD51L3,
XRCC2, and XRCC3 ). Notably, the expression of the sixth
paralog, DMC1, and of RAD51 (data not shown) was not
Figure 2. EZH2 overexpression reduces RAD51 foci formation. (A) Visualization of RAD51 foci in MCF10A cells infected with vector control or av-EZH2 after
etoposide-induced DSBs. Shown are two representative cells. Lower panel: respective DAPI stain. (B) Mean percentage of vector control or av-EZH2 cells containing
z10RAD51 foci (columns) after a 24-hour etoposide treatment. Standard deviations (error bars) from three independent experiments for each time point are depicted.
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affected by EZH2. In light of these data, it is likely that EZH2
may play a role in the transcriptional regulation of the RAD51
paralogs and thus modulate the function of HR DNA repair.
In Drosophila, PcG exert their function through a DNA motif
called Polycomb response element (PRE) [61,62]. Although
a mammalian PRE has not been found yet, a recent study
found that the EZH2 complex is able to associate with the
hDAB2IP promoter in prostate cells and is able to recruit
HDAC1 to the promoter region [19]. Whether the EZH2
complex also associates with the promoters of the RAD51
paralogs is intriguing and warrants investigation.
Consistent with the observed decrease in RAD51L1,
RAD51L2, RAD51L3, XRCC2, and XRCC3, EZH2-over-
expressing mammary epithelial cells had an attenuated
Figure 3. EZH2 overexpression decreases cell survival following etoposide treatment and ionizing radiation. MCF10A, MCF7, and SUM102 cells were infected with
av-EZH2 and the control vector. (A) Western blot analysis for EZH2 and -actin. (B) Three independent toxicity assays for MCF10A, MCF7, and SUM102 cells. The
legend for all experiments is shown in the upper right corner. The upper panel shows a colony outgrowth of cells infected with av-EZH2, a luciferase control, or a
vector control. Cells were treated continuously with etoposide. Colony-forming ability was measured after 7 to 9 days by counting colonies with more than 50 cells.
The means (symbols) and standard deviations (bars) from three different experiments are shown. The middle panel shows clonogenic efficiency after 24 hours of
treatment with etoposide. The means (symbols) and standard deviations (bars) from four different experiments are shown. The lower panel shows the surviving
cells after different doses of ionizing irradiation. Colonies were counted after 9 days, as described above.
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formation of RAD51 repair foci after treatment with etopo-
side. EZH2 overexpression resulted in a marked decrease
in the number of cells with repair foci when compared to con-
trols. The attenuated RAD51 foci formation most likely led
to unrepaired chromosomal breaks. Although most cells
would succumb to the damage, a subset of cells may survive
and acquire additional genetic alterations, which may lead to
neoplastic transformation.
We next tested the hypothesis that attenuated DNA repair
foci formation may lead to defective HR. Indeed, EZH2-
overexpressing cells exhibited decreased survival ability
following etoposide and ionizing radiation, both of which
cause DNA DSBs that necessitate HR repair [42,63–67].
EZH2 overexpression not only affected HR repair in the
spontaneously immortalized human mammary epithelial
cell line MCF10A, but had a similar effect on two breast
cancer cell lines MCF7 and SUM102. Furthermore, EZH2-
overexpressing MCF10A cells exhibited an increase in the
number of chromosomes when compared to controls. These
results are not surprising given the important role of HR not
only in DNA repair, but also in the resolution of crossover
during cell divisions [32]. Taken together, our data suggest
that EZH2 overexpression occurs early in neoplastic trans-
formation and may be important for the development of
prevention strategies for breast cancer based on blockade
of EZH2. Our data open the way to future investigations on
the detection of EZH2 overexpression in histologically nor-
mal breast epithelial cells as a harbinger of carcinoma. This
could result in the development of a new clinically applicable
tissue-based test to determine the individual risk of breast
cancer before histologic atypia is evident.
Our data are in agreement with previous studies demon-
strating that aneuploidy is particularly seen in association
with defects in HR, but not in association with defects in other
DNA repair mechanisms such as NHEJ repair [32,46,47].
These data suggest further investigations to elucidate
whether EZH2 overexpression induces random or specific
chromosomal alterations. Our data strengthen the emerging
link between decreased expression of the RAD51 paralogs,
aneuploidization, and cancer development.
In summary, we have identified and delineated a new
functional role for EZH2 in the HR mechanism of DNA repair,
which may cause aneuploidy in breast epithelial cells. We
provide a mechanistic basis for our initial observations im-
plicating EZH2 in promoting breast cancer development and
also uncover a role for EZH2 in the regulation of a central
pathway in DNA repair and in maintaining the stability of
the genome.
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